Phenylbutanoic Acid

Phenylbutanoic Acid

SCHEMBL5657539

NC(=O)c1ccc(Br)cc1O.O=C(O)CCCc1ccccc1

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 5/20 0.55
HDAC3 O15379 3/20 0.55
HDAC2 Q92769 3/20 0.55
HDAC8 Q9BY41 3/20 0.55
HDAC6 Q9UBN7 3/20 0.55
HDAC5 Q9UQL6 3/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
HDAC4 P56524 2/20 0.55
HDAC7 Q8WUI4 2/20 0.55
HDAC10 Q969S8 2/20 0.55
HDAC11 Q96DB2 2/20 0.55
HDAC9 Q9UKV0 2/20 0.55
MAPK1 P28482 1/20 0.55
ADRA1A P35348 1/20 0.55
SLC6A3 Q01959 1/20 0.55
PLA2G10 O15496 2/20 0.51
PLA2G2A P14555 2/20 0.51
MAPT P10636 1/20 0.49
RXFP1 Q9HBX9 1/20 0.49
NPC1 O15118 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phenylbutanoic Acid SCHEMBL5657068 0.81 HDAC1 (0.58) HDAC1HDAC3HDAC2HDAC8HDAC6
Phenylbutanoic Acid SCHEMBL2061054 0.79 HDAC3 (0.64) HDAC1HDAC3HDAC2HDAC8HDAC6
SCHEMBL13740129 0.78 DGAT1 (0.62) MAPTRXFP1NPC1CYP1A2LMNA
SCHEMBL20576964 0.77 MAPT (0.54) HDAC2HDAC8HDAC6SMN1; SMN2MAPT
SCHEMBL5657536 0.77 ALOX15 (0.57) MAPTRAB9A
Phenylbutanoic Acid SCHEMBL1716 0.74 HDAC1 (1.00) HDAC1HDAC3HDAC2HDAC8HDAC6
Phenylbutanoic Acid SCHEMBL21219015 0.74 HDAC1 (1.00) HDAC1HDAC3HDAC2HDAC8HDAC6
Phenylbutanoic Acid SCHEMBL1021513 0.74 HDAC1 (1.00) HDAC1HDAC3HDAC2HDAC8HDAC6
Phenylbutanoic Acid SCHEMBL5657063 0.74 CYP1A1 (0.63) HDAC1HDAC3HDAC2HDAC8HDAC6
SCHEMBL15270886 0.74 POLB (0.49) HDAC1HDAC3HDAC2HDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260077020-A1 ORAL PEPTIDE PHARMACEUTICAL COMPOSITION THAT FACILITATES ENHANCED ORAL ABSORPTION LE ROUX DANIELLE MARIE (US) 2026-03-19 US disclosed
US-7071214-B2 Compounds and compositions for delivering active agents EMISPHERE TECHNOLOGIES, INC. (US) 2006-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260077020-A1 ORAL PEPTIDE PHARMACEUTICAL COMPOSITION THAT FACILITATES ENHANCED ORAL ABSORPTION VIP, GIPR, SLC10A2 HDAC1 572/4885HDAC3 847/4885HDAC2 478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.